Tentori L - Search Results

1

Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?

Franzese O, Battaini F, Graziani G, Tentori L, Barbaccia ML, Aquino A, Roselli M, Fuggetta MP, Bonmassar E, Torino F. Franzese O, et al. Among authors: tentori l. Pharmacol Res. 2018 May;131:1-6. doi: 10.1016/j.phrs.2018.03.005. Epub 2018 Mar 9. Pharmacol Res. 2018. PMID: 29530602 Review.

2

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

Tentori L, Portarena I, Graziani G. Tentori L, et al. Pharmacol Res. 2002 Feb;45(2):73-85. doi: 10.1006/phrs.2001.0935. Pharmacol Res. 2002. PMID: 11846617 Review.

3

Chemopotentiation by PARP inhibitors in cancer therapy.

Tentori L, Graziani G. Tentori L, et al. Pharmacol Res. 2005 Jul;52(1):25-33. doi: 10.1016/j.phrs.2005.02.010. Pharmacol Res. 2005. PMID: 15911331 Review.

4

Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

Tentori L, Graziani G. Tentori L, et al. Pharmacol Res. 2007 May;55(5):359-69. doi: 10.1016/j.phrs.2007.01.020. Epub 2007 Feb 3. Pharmacol Res. 2007. PMID: 17349798 Review.

5

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P. Graziani G, et al. Among authors: tentori l. Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review.

6

Pharmacological strategies to increase the antitumor activity of methylating agents.

Tentori L, Graziani G. Tentori L, et al. Curr Med Chem. 2002 Jul;9(13):1285-301. doi: 10.2174/0929867023369916. Curr Med Chem. 2002. PMID: 12052167 Review.

7

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Tentori L, et al. Glia. 2002 Oct;40(1):44-54. doi: 10.1002/glia.10113. Glia. 2002. PMID: 12237842

8

Recent approaches to improve the antitumor efficacy of temozolomide.

Tentori L, Graziani G. Tentori L, et al. Curr Med Chem. 2009;16(2):245-57. doi: 10.2174/092986709787002718. Curr Med Chem. 2009. PMID: 19149575 Review.

9

Challenging resistance mechanisms to therapies for metastatic melanoma.

Tentori L, Lacal PM, Graziani G. Tentori L, et al. Trends Pharmacol Sci. 2013 Dec;34(12):656-66. doi: 10.1016/j.tips.2013.10.003. Epub 2013 Nov 7. Trends Pharmacol Sci. 2013. PMID: 24210882 Review.

10

Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.

Lacal PM, Atzori MG, Ruffini F, Scimeca M, Bonanno E, Cicconi R, Mattei M, Bernardini R, D'Atri S, Tentori L, Graziani G. Lacal PM, et al. Among authors: tentori l. Pharmacol Res. 2020 Sep;159:104957. doi: 10.1016/j.phrs.2020.104957. Epub 2020 May 30. Pharmacol Res. 2020. PMID: 32485280

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page